EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics

Johnathan Arnon, Gal Dinstag, Omer Tirosh, Leon Gugel, Yaron Kinar, Tzivia Gottlieb, Anna Elia, Yakir Rottenberg, Hovav Nechushtan, Michael Tabi, Philip Blumenfeld, Eli Pikarsky und 3 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Johnathan Arnon und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sharett Institue of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel arnony@hadassah.org.il gal@pangeabiomed.com. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adenocarcinoma of Lung, Lung Neoplasms, Transcriptome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors (ICI) have improved outcomes in non-small cell lung cancer (NSCLC). Nevertheless, the clinical benefit of ICI as monotherapy or in combination with chemotherapy remains widely varied and existing biomarkers have limited predictive value. We present an analysis of ENLIGHT-DP, a novel transcriptome-based biomarker directly from histopathology slides, in patients with lung adenocarcinoma (LUAD) treated with ICI and platinum-based chemotherapy.

Methods

We retrospectively scanned high-resolution H&E slides from pretreatment tumor-tissue samples of 50 patients with metastatic LUAD treated with first-line ICI with (46) or without (4) platinum-based chemotherapy and applied our ENLIGHT-DP pipeline to generate, in a blinded manner, an individual prediction score. ENLIGHT-DP predicts response to ICI and targeted therapies given H&E slide scans in two steps: (1) predict individual messenger RNA expression directly from high-resolution H&E scanned slides using DeepPT, a digital-pathology-based algorithm. (2) Use these values as input to ENLIGHT, a transcriptome-based platform that predicts response to ICI and targeted therapies derived from drug-specific networks of gene expressions. We then unblinded the clinical outcomes and evaluated the predictive value of ENLIGHT-DP in comparison to programmed death ligand (PD-L)-1 and tumor mutational burden (TMB).

Results

ENLIGHT-DP is predictive of response to treatment with receiver operating characteristic (ROC) area under the curve (AUC) of 0.69 (p=0.01) and outperforms both TMB and PD-L1 expression with ROC AUC of 0.52 and 0.46, respectively. Using a predetermined binary cut-off (established on independent cohorts) for patients predicted to respond to ICI, ENLIGHT-DP achieves 100% positive predictive value (PPV) and 44% sensitivity, superior to both PD-L1>50% (65% PPV and 38% sensitivity) and TMB-high (82% PPV and 26% sensitivity). ENLIGHT-DP was highly predictive in PD-L1

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsAdenocarcinoma of LungLung NeoplasmsTranscriptomeBiomarkers, TumorPlatinumAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedPredictive Value of Tests

Stichwörter der Autor:innen

AdenocarcinomaBiomarkerGene expression profiling - GEPImmune Checkpoint InhibitorLung Cancer

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorPlatinum

Autor:innen und Institutionen

  • Sharett Institue of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel arnony@hadassah.org.il gal@pangeabiomed.com.
  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Pangea Biomed, Tel Aviv, Israel arnony@hadassah.org.il gal@pangeabiomed.com.
  • Pangea Biomed, Tel Aviv, Israel.
  • Department of Pathology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Sharett Institue of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Zitieren

APA

Arnon, J., Dinstag, G., Tirosh, O., Gugel, L., Kinar, Y., Gottlieb, T., Elia, A., Rottenberg, Y., Nechushtan, H., Tabi, M., Blumenfeld, P., Pikarsky, E., Beker, T., Aharonov, R., & Popovtzer, A. (2025). Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010132

Vancouver

Arnon J, Dinstag G, Tirosh O, Gugel L, Kinar Y, Gottlieb T, et al. Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010132

BibTeX
@article{Arnon2025,
  author = {Arnon, Johnathan and Dinstag, Gal and Tirosh, Omer and Gugel, Leon and Kinar, Yaron and Gottlieb, Tzivia and Elia, Anna and Rottenberg, Yakir and Nechushtan, Hovav and Tabi, Michael and Blumenfeld, Philip and Pikarsky, Eli and Beker, Tuvik and Aharonov, Ranit and Popovtzer, Aron},
  title = {Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010132}
}
Kostenlos starten →